/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Cellectar Biosciences Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.56 0.0193(1.93%) CLRB at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 3.56
Highest Today 3.8
Today’s Open 3.56
Prev. Close 3.62
52 Week High 44.70
52 Week Low 2.71
Day’s Range: Low 3.56 High 3.8
52-Week Range: Low 2.71 High 44.70
1 day return -
1 Week return +2.78
1 month return +9.17
3 month return -26.2
6 month return +693.54
1 year return +151.02
3 year return +97.32
5 year return -82.0
10 year return -

Institutional Holdings

Vanguard Group Inc 1.77

Vanguard Total Stock Mkt Idx Inv 1.10

Geode Capital Management, LLC 0.45

Vanguard Institutional Extnd Mkt Idx Tr 0.41

HRT FINANCIAL LLC 0.39

Riverview Capital Advisers LLC 0.33

Fidelity Extended Market Index 0.24

BlackRock Inc 0.15

Dimensional US Small Cap ETF 0.14

UBS Group AG 0.11

Extended Equity Market Fund K 0.07

Fidelity Total Market Index 0.06

NT Ext Equity Mkt Idx Fd - NL 0.06

Spartan Extended Market Index Pool F 0.06

Fidelity Series Total Market Index 0.05

Northern Trust Extended Eq Market Idx 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

Spartan Total Market Index Pool G 0.03

Vanguard U.S. Eq Idx £ Acc 0.02

Morgan Stanley - Brokerage Accounts 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

Goldman Sachs Group Inc 0.01

State St US Extended Mkt Indx NL Cl C 0.01

Extended Equity Market Fund M 0.01

SIMPLEX TRADING, LLC 0.01

Tower Research Capital LLC 0.01

SSgA U.S. Total Market Index Strategy 0.00

Group One Trading, LP 0.00

Advisor Group Holdings, Inc. 0.00

SBI Securities Co Ltd 0.00

Bank of America Corp 0.00

JONES FINANCIAL COMPANIES LLLP 0.00

U.S. Bancorp 0.00

Bfsg, LLC 0.00

Citigroup Inc 0.00

HARBOUR INVESTMENTS, INC. 0.00

State Street Corp 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 15.35 M

PB Ratio 2.036

PE Ratio 0.0

Enterprise Value 3.62 M

Total Assets 25.47 M

Volume 49221

Company Financials

Annual Revenue FY24:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:-192375 -0.2M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-37983496 -38.0M, FY23:-37749931 -37.7M, FY22:-28601254 -28.6M, FY21:-23970163 -24.0M, FY20:-14756542 -14.8M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-52277 -0.1M, Q2/2025:null 0.0M, Q1/2025:-56295 -0.1M, Q3/2024:-66021 -0.1M, Q2/2024:null 0.0M

Quarterly Net worth Q3/2025:-4443877 -4.4M, Q2/2025:-5447911 -5.4M, Q1/2025:-6604029 -6.6M, Q3/2024:-14664719 -14.7M, Q2/2024:-919371 -0.9M

Fund house & investment objective

Company Information Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Organisation Biotechnology

Employees 11

Industry Biotechnology

CEO Mr. James V. Caruso

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow